Aikaterini Gatsiou

Dr. Aikaterini Gatsiou

Newcastle University
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2016 in Nature Medicine
Verified
Journal Article
Closed access
Konstantinos StellosKonstantinos Stellos
Konstantinos Stellos
Aikaterini GatsiouAikaterini Gatsiou
Aikaterini Gatsiou
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
LMLjubica Perisic Matic
Ljubica Perisic Matic
DJDavid John
David John
DBDittmar Böckler
Dittmar Böckler

1 March 2015 in JACC
Verified
Journal Article
Closed access
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
DSDirk Sibbing
Dirk Sibbing
LRLoukianos S. Rallidis
Loukianos S. Rallidis
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
DSDimitrios Stakos
Dimitrios Stakos
Konstantinos StellosKonstantinos Stellos
Konstantinos Stellos

1 January 2020 in Journal of Autoimmunity
Verified
Journal Article
Open access
NVNikolaos I. Vlachogiannis
Nikolaos I. Vlachogiannis
Aikaterini GatsiouAikaterini Gatsiou
Aikaterini Gatsiou
Domenico Alessandro SilvestrisDomenico Alessandro Silvestris
Domenico Alessandro Silvestris
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
MTMaria G. Tektonidou
Maria G. Tektonidou
Konstantinos StellosKonstantinos Stellos
Konstantinos Stellos
Adenosine-to-inosine (A-to-I) RNA editing of Alu retroelements is a primate-specific mechanism mediated by adenosine deaminases acting on RNA (ADARs) that diversifies transcriptome by changing selected nucleotides in RNA molecules. We tested the hypothesis that A-to-I RNA editing is altered in rheumatoid arthritis (RA). Synovium expression analysis of ADAR1 was investigated in 152 RA patients and 50 controls. Peripheral blood mononuclear cells derived from 14 healthy subjects and 19 patients with active RA at baseline and after 12-week treatment were examined for ADAR1p150 and ADAR1p110 isoform expression by RT-qPCR. RNA editing activity was analysed by AluSx+ Sanger-sequencing of cathepsin S, an extracellular matrix degradation enzyme involved in antigen presentation. ADAR1 was significantly over-expressed in RA synovium regardless of disease duration. Similarly, ADAR1p150 isoform expression was significantly increased in the blood of active RA patients. Individual nucleotide analysis revealed that A-to-I RNA editing rate was also significantly increased in RA patients. Both baseline ADAR1p150 expression and individual adenosine RNA editing rate of cathepsin S AluSx+ decreased after treatment only in those patients with good clinical response. Upregulation of the expression and/or activity of the RNA editing machinery were associated with a higher expression of edited Alu-enriched genes including cathepsin S and TNF receptor-associated factors 1,2,3 and 5. A previously unrecognized regulation and role of ADAR1p150-mediated A-to-I RNA editing in post-transcriptional control in RA underpins therapeutic response and fuels inflammatory gene expression, thus representing an interesting therapeutic target.

25 July 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
ALAgeliki Laina
Ageliki Laina
Aikaterini GatsiouAikaterini Gatsiou
Aikaterini Gatsiou
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
KSKimon Stamatelopoulos
Kimon Stamatelopoulos
Konstantinos StellosKonstantinos Stellos
Konstantinos Stellos
Since our knowledge on structure and function of messenger RNA (mRNA) has expanded from merely being an intermediate molecule between DNA and proteins to the notion that RNA is a dynamic gene regulator that can be modified and edited, RNA has become a focus of interest into developing novel therapeutic schemes. Therapeutic modulation of RNA molecules by DNA- and RNA-based therapies has broadened the scope of therapeutic targets in infectious diseases, cancer, neurodegenerative diseases and most recently in cardiovascular diseases as well. Currently, antisense oligonucleotides (ASO), small interfering RNAs (siRNAs), and microRNAs are the most widely applied therapeutic strategies to target RNA molecules and regulate gene expression and protein production. However, a number of barriers have to be overcome including instability, inadequate binding affinity and delivery to the tissues, immunogenicity, and off-target toxicity in order for these agents to evolve into efficient drugs. As cardiovascular diseases remain the leading cause of mortality worldwide, a large number of clinical trials are under development investigating the safety and efficacy of RNA therapeutics in clinical conditions such as familial hypercholesterolemia, diabetes mellitus, hypertriglyceridemia, cardiac amyloidosis, and atrial fibrillation. In this review, we summarize the clinical trials of RNA-targeting therapies in cardiovascular disease and critically discuss the advances, the outcomes, the limitations and the future directions of RNA therapeutics in precision transcriptomic medicine.

1 November 2021 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Open access
NVNikolaos I. Vlachogiannis
Nikolaos I. Vlachogiannis
MSMarco Sachse
Marco Sachse
GGGeorgios Georgiopoulos
Georgios Georgiopoulos
EZEleftherios Zormpas
Eleftherios Zormpas
DBDimitrios Bampatsias
Dimitrios Bampatsias
Konstantinos StellosKonstantinos Stellos
Konstantinos Stellos
Long non-coding RNAs (lncRNAs) have emerged as critical regulators in human disease including atherosclerosis. However, the mechanisms involved in the post-transcriptional regulation of the expression of disease-associated lncRNAs are not fully understood. Gene expression studies revealed that Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) lncRNA expression was increased by >2-fold in peripheral blood mononuclear cells (PBMCs) derived from patients with coronary artery disease (CAD) or in carotid artery atherosclerotic plaques. We observed a linear association between NEAT1 lncRNA expression and prevalence of CAD which was independent of age, sex, cardiovascular traditional risk factors and renal function. NEAT1 expression was induced by TNF-α, while silencing of NEAT1 profoundly attenuated the TNF-α-induced vascular endothelial cell pro-inflammatory response as defined by the expression of CXCL8, CCL2, VCAM1 and ICAM1. Overexpression of the RNA editing enzyme adenosine deaminase acting on RNA-1 (ADAR1), but not of its editing-deficient mutant, upregulated NEAT1 levels. Conversely, silencing of ADAR1 suppressed the basal levels and the TNF-α-induced increase of NEAT1. NEAT1 lncRNA expression was strongly associated with ADAR1 in CAD and peripheral arterial vascular disease. RNA editing mapping studies revealed the presence of several inosines in close proximity to AU-rich elements within the AluSx3+/AluJo- double-stranded RNA complex. Silencing of the stabilizing RNA-binding protein AUF1 reduced NEAT1 levels while silencing of ADAR1 profoundly affected the binding capacity of AUF1 to NEAT1. Together, our findings propose a mechanism by which ADAR1-catalyzed A-to-I RNA editing controls NEAT1 lncRNA stability in ASCVD.

7 February 2014 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
STStergios Tzikas
Stergios Tzikas
DSDennis Schlak
Dennis Schlak
KSKateryna Sopova
Kateryna Sopova
Aikaterini GatsiouAikaterini Gatsiou
Aikaterini Gatsiou
DSDimitrios Stakos
Dimitrios Stakos
CLChristoph Laske
Christoph Laske
Background: Increasing evidence supports the role of cardiovascular risk factors in the development of Alzheimer’s disease (AD). Objective: In the present pilot study, we investigated plasma concentrations of myeloperoxidase (MPO) and its possible as